With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Unfounded cancer cures, dubious anti-vaccine narratives, and false claims that neurological disorders can be "reversed" through diets: influential American and European podcasters are peddling ...

Course- based Undergraduate Research Experiences (CUREs) by incorporating nine essential elements of research, relevance, scientific background, hypothesis development, research proposal, all aspects ...

Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

The recovery can extend from anywhere between six to 12 months and occasionally up to three years. Currently, there is no certain cure for Guillain-Barré Syndrome. The paralysis not only affects the ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

“[By] using these techniques, I now offer a holistic and comprehensive treatment that promises not just relaxation, but transformative rejuvenation” — which is, exactly where the cultural ...

The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent adverse events occurred in 80% and 81% of dazukibart 150 mg and 160 mg groups.